Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.58 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8848096 | 1.00 | NAAA (0.61) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL15688611 | 1.00 | NAAA (0.61) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL8847557 | 0.98 | KEAP1 (0.60) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL30884882 | 0.97 | NAAA (0.57) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL628952 | 0.93 | KEAP1 (0.57) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL6359085 | 0.91 | KEAP1 (0.55) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL641051 | 0.90 | CASP2 (0.55) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL15680573 | 0.88 | KEAP1 (0.66) | KEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL6627703 | 0.87 | KEAP1 (0.52) | NAAAKEAP1NFE2L2EPHX1EPHX2 | |
| SCHEMBL8848512 | 0.86 | EPHX2 (0.55) | KEAP1NFE2L2EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | NAAA 294/4885KEAP1 142/4885NFE2L2 842/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | NAAA 407/4885KEAP1 123/4885NFE2L2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.